Europe’s drug regulator, namely the European Medicines Agency (EMA) has defended the use of the Coronavirus vaccine developed by AstraZeneca/Oxford University, despite growing fears over blood clots in some people inoculated with the jab.
“The number of thromboembolic events overall in vaccinated people seems not to be higher than that seen in the general population,” EMA said in a statement issued on Tuesday, backing the assessment by the World Health Organisation (WHO), which said there wa…
This story is part of New Europe’s Premium content.
| To Read the Full Story, Subscribe or Sign In from the ↑ Top of the Page ↑ |
In this article:
